MedPath

Study Reveals Impact of Cholesterol Changes on Cardiovascular Disease Risk

A recent analysis of the PROMINENT trial and the Copenhagen General Population Study highlights the effects of changes in remnant cholesterol, LDL cholesterol, and apolipoprotein B on the risk of atherosclerotic cardiovascular disease, showing neutral outcomes despite significant lipid alterations.

The PROMINENT trial, focusing on the triglyceride- and remnant cholesterol-lowering agent pemafibrate, demonstrated neutral results in cardiovascular outcomes despite notable reductions in plasma triglycerides and remnant cholesterol. This study aimed to explore whether absolute mass changes in remnant cholesterol, LDL cholesterol, and apolipoprotein B could elucidate the trial's outcomes.
In the trial, pemafibrate treatment led to a -7 mg/dL change in remnant cholesterol, a +10 mg/dL change in LDL cholesterol, and a +5 mg/dL change in apolipoprotein B. The Copenhagen General Population Study (CGPS) mirrored these changes to estimate their impact on atherosclerotic cardiovascular disease (ASCVD) risk, defined by cardiovascular death, myocardial infarction, ischemic stroke, and coronary revascularization.
The analysis revealed hazard ratios for ASCVD of 0.97 for a -7 mg/dL change in remnant cholesterol, 1.04 for a +10 mg/dL change in LDL cholesterol, and 1.02 for a +5 mg/dL change in apolipoprotein B. When combining these changes, the estimated hazard ratio for ASCVD was 1.05 in the CGPS, closely aligning with the 1.03 observed in the PROMINENT trial.
These findings suggest that while pemafibrate effectively alters lipid profiles, the combined effects of these changes on ASCVD risk are minimal, underscoring the complexity of lipid management in cardiovascular disease prevention.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Acoramidis Shows Sustained Benefit in ATTR-CM Patients: Open-Label Extension Data

Acoramidis demonstrates sustained improvement in cardiovascular outcomes, reducing the risk of cardiovascular hospitalization or all-cause mortality in ATTR-CM patients.
The open-label extension study reveals a statistically significant 36% reduction in all-cause mortality at 36 months with continuous acoramidis treatment.

Plozasiran Shows Promise in Reducing Triglycerides in Familial Chylomicronemia Syndrome and Severe Hypertriglyceridemia

Phase 3 PALISADE study reveals plozasiran significantly reduces triglycerides in patients with Familial Chylomicronemia Syndrome (FCS), regardless of genetic confirmation.
Open-label extension of Phase 2 MUIR and SHASTA-2 studies demonstrates sustained triglyceride reductions with plozasiran in severe hypertriglyceridemia patients over 15 months.

Fluctuating Cholesterol Levels Linked to Increased Dementia Risk in Older Adults

Study finds that significant year-to-year variability in total cholesterol and LDL-C levels is associated with a higher risk of dementia and cognitive decline in older adults.
High cholesterol fluctuations were linked to a 60% increase in dementia risk and a 23% increase in cognitive decline, independent of statin use.

CCTA-Guided Lipid Management Strategy Trial in Asymptomatic Individuals

The RESPECT2 trial is evaluating a CCTA-guided strategy for lipid management versus usual care in asymptomatic individuals aged 40-69 in Nanjing, China.
The primary outcome measures the proportion of participants regularly taking lipid-lowering medication at 6 and 12 months.

Intensive Blood Pressure Lowering Linked to Improved Stroke-Free Survival in High-Risk Patients

A pooled analysis of SPRINT and ACCORD-BP trials reveals that intensive blood pressure control (target <120 mmHg) is associated with improved stroke-free survival.
The study defined stroke-free survival as the time to either death or stroke, whichever occurred first, providing a clinically relevant composite endpoint.

Low Incidence of Cardiovascular Events with Immune Checkpoint Inhibitors Reported in Meta-Analysis

A meta-analysis of 589 trials indicates a low incidence (0.80%) of cardiovascular adverse events (CVAEs) in patients treated with anti-programmed cell death 1 and/or programmed cell death ligand 1 inhibitors.
Myocarditis incidence was significantly higher after treatment with dual immune checkpoint inhibitors, but CVAE incidence was not elevated with ICI combination therapies or tyrosine kinase inhibitors.

Flexible Antiplatelet Management Safe After Drug-Eluting Stent Implantation

A recent trial suggests that discontinuing antiplatelet therapy around non-cardiac surgery is non-inferior to continuing aspirin monotherapy for patients with prior drug-eluting stent (DES) implantation.
The ASSURE DES trial found no significant difference in the composite outcome of death, myocardial infarction, stent thrombosis, or stroke between the two antiplatelet strategies.

Prucalopride Shows Favorable Safety Profile in Chronic Idiopathic Constipation Treatment

Prucalopride, a selective 5-HT4 receptor agonist, demonstrates a manageable safety profile in treating chronic idiopathic constipation (CIC) based on clinical trial data.
Common adverse reactions reported in prucalopride-treated patients include headache, abdominal pain, nausea, and diarrhea, with most cases resolving within a few days.

Double-Blind Trial Shows Comparable Efficacy in Treatment and Control Groups for Gastric Symptoms

A recent double-blind, non-inferiority, randomized controlled trial evaluated the efficacy of a treatment for various gastric symptoms, comparing it against a control group. The study found no statistically significant differences in clinical effective rates, symptom relief, and disappearance rates between the two groups, indicating comparable efficacy.

Comparative Analysis of PARP Inhibitors in BRCA-Mutated Ovarian Cancer Shows Similar Efficacy and Toxicity

A network meta-analysis of PARP inhibitors (PARPi) in BRCA-mutated ovarian cancer reveals no significant differences in efficacy among various regimens used in upfront or relapsed settings.
The study assesses the cost-effectiveness of PARPi regimens using the ASCO value framework, indicating similar clinical benefits, toxicity, and net health benefit across different treatments.

Reference News

[1]
Remnant cholesterol, LDL cholesterol, and apoB absolute ...
pubmed.ncbi.nlm.nih.gov · Jun 11, 2024

The PROMINENT trial found neutral cardiovascular outcomes with pemafibrate despite reducing triglycerides and remnant ch...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy